Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Pharma Mar SG&A Expense (TTM) : 73.98M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 73.98M |
| March 31, 2026 | 70.72M |
| December 31, 2025 | 67.22M |
| September 30, 2025 | 61.19M |
| June 30, 2025 | 56.92M |
| March 31, 2025 | 53.50M |
| December 31, 2024 | 50.99M |
| September 30, 2024 | 49.15M |
| June 30, 2024 | 47.08M |
| March 31, 2024 | 46.54M |
| December 31, 2023 | 45.19M |
| September 30, 2023 | 48.32M |
| June 30, 2023 | 49.56M |
| March 31, 2023 | 49.43M |
| December 31, 2022 | 55.10M |
| June 30, 2022 | 51.04M |
| March 31, 2022 | 50.95M |
| December 31, 2021 | 50.84M |
| September 30, 2021 | 44.82M |
| June 30, 2021 | 41.99M |
| March 31, 2021 | 41.13M |
| December 31, 2020 | 40.67M |
| September 30, 2020 | 41.02M |
| June 30, 2020 | 42.09M |
| March 31, 2020 | 43.64M |
| Date | Value |
|---|---|
| December 31, 2019 | 42.35M |
| September 30, 2019 | 42.89M |
| June 30, 2019 | 43.66M |
| March 31, 2019 | 60.58M |
| December 31, 2018 | 61.76M |
| September 30, 2018 | 66.77M |
| June 30, 2018 | 75.79M |
| March 31, 2018 | 66.69M |
| December 31, 2017 | 71.73M |
| September 30, 2017 | 74.33M |
| June 30, 2017 | 74.09M |
| March 31, 2017 | 73.93M |
| December 31, 2016 | 75.24M |
| September 30, 2016 | 75.12M |
| June 30, 2016 | 76.65M |
| March 31, 2016 | 77.49M |
| December 31, 2015 | 76.05M |
| September 30, 2015 | 76.52M |
| June 30, 2015 | 75.24M |
| March 31, 2015 | 77.98M |
| December 31, 2014 | 80.86M |
| September 30, 2014 | 81.94M |
| June 30, 2014 | 83.63M |
| March 31, 2014 | 82.17M |
| December 31, 2013 | 80.99M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Oryzon Genomics SA | 3.389M |
| Grifols SA | 1.318B |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alkermes Plc | 841.17M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |